Skip to content
Arlington, VA

PARASOL-MN INTERIM MEETING

September 23-24, 2026
Arlington, Virginia (and virtual)

PARASOL_Logo[22368]

Proteinuria and Other Biomarkers as Endpoints for Clinical Trials in Kidney Disease

REGISTRATION

The PARASOL-MN project is part of an international, multi-stakeholder effort to accelerate progress in kidney disease and explore potential surrogate endpoints for clinical trials. PARASOL brings together patients, clinicians, researchers, industry, and regulators around shared data and common goals.

The PARASOL-MN Interim Meeting will bring together global leaders in membranous nephropathy to review emerging data from the PARASOL registry and advance a shared roadmap for future clinical trials. This focused working meeting will convene investigators, statisticians, regulators, industry partners, and patient advocates to examine interim analyses, discuss assay and data harmonization, and explore implications for MN studies, including eligibility criteria, endpoints, follow-up strategies, and integration of real-world data.

Through a mix of plenary updates and interactive discussion, participants will have the opportunity to stress-test proposed approaches, surface gaps and operational challenges, and align on practical next steps for the MN community. The meeting is designed not as a passive conference, but as a collaborative working session—shaping how PARASOL-MN data will be used to accelerate high-quality, patient-centered trials and inform future regulatory conversations.

Register by September 8 to be part of the conversation and help shape the progress ahead. If you can't join us in person, select the virtual option when registering and we will follow up with details to join remotely.
 
IMG_8759 Large
At the PARASOL-MN kickoff meeting (October 2025, Minneapolis)

ABOUT THE WORKSHOP

BACKGROUND

The PARASOL (Proteinuria and Other Biomarkers as Endpoints for Clinical Trials in Kidney Disease) project is a global, multi-stakeholder collaboration created in 2023 to tackle barriers to efficient kidney disease trials—starting with FSGS and then expanding to APOL1-associated kidney disease and membranous nephropathy. Led by academic investigators and kidney health nonprofits working in close collaboration with regulators and patient representatives, PARASOL has built a shared data and analytics platform that brings together longitudinal registry data, detailed phenotyping, and rigorous statistical methods to better understand disease trajectories and potential surrogate endpoints. Through a series of focused workshops and webinars, the consortium has created a common language around disease definitions, harmonized trial endpoints, and developed practical guidance for using real-world data to inform study design.

To date, PARASOL has delivered proof-of-concept that pooled registry and longitudinal data can be used to evaluate candidate surrogate endpoints, clarify inclusion criteria, and de-risk rare kidney disease trials for sponsors and investigators. Building on this foundation, the current phase of PARASOL is focused on expanding disease areas, deepening analytic work on endpoints and subgroups, and strengthening partnerships with regulators and industry to translate findings into actionable trial strategies and future guidance. The overarching goal is to create a sustainable, scalable platform that accelerates the development of effective therapies for rare and complex kidney diseases by aligning stakeholders around shared data, shared methods, and a shared vision for more efficient, patient-centered trials.

Goals and Objectives

The goal of this meeting is to advance the understanding of potential surrogate endpoints for approval of new treatments for primary membranous nephropathy. The interim meeting will be used to discuss the results of the initial PARASOL-MN analyses and engage in a data-driven discussion to steer next steps in the project.

Who Should Attend This working meeting is limited to those participating in the PARASOL project (e.g. by contributing data, biostatistical analysis, etc.) along with invited regulatory partners and selected industry stakeholders. The PARASOL community is inclusive, collaborative, and open to new members. If you are interested in participating, please contact parasol@is-gd.org.

ORGANIZERS

This workshop is led by the International Society of Glomerular Disease, with support from NephCure, the National Kidney Foundation, and the Kidney Health Initiative (KHI) of the American Society of Nephrology.

PARASOL-MN LEADERSHIP

International Society of Glomerular Disease (Project Oversight & Operations)

 

Barbara Gillespie, Chief Medical & Strategy Officer

Laurel Damashek, Chief Operating Officer

 

 

Primary Investigators

Patrick Nachman, University of Minnesota
Tobias B. Huber, UKE Hamburg-Eppendorf

 

 

Senior Advisors

Brad Rovin, The Ohio State University
Matthias Kretzler, University of Michigan
Laura Mariani, University of Michigan

 

 

Data Analysis / Biostatistics Lead

 

Jarcy Zee, University of Pennsylvania

 

 

Additional Biostatistics

 

Vivek Charu, Stanford University

Alex Mercer, JAMCO

Abigail Smith, Northwestern University (Advisory)

 

 

Data Coordinating Center Operations

Hailey Desmond, University of Michigan

Ashley Rahimi, University of Michigan